Clinical Trial Update: A Study of EXG102-031 in Participants With wAMD [Phase 1, Phase 2]

View source ↗

Summary

A study update for EXG102-031 investigating its safety and efficacy in neovascular age-related macular degeneration across Phase 1 and Phase 2 stages.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neovascular Age-related Macular Degeneration

Drugs mentioned

• EXG102-031

Snippet

Sponsor: Guangzhou Jiayin Biotech Ltd | Conditions: Neovascular Age-related Macular Degeneration | Phase 1, Phase 2 | Status: UNKNOWN